



Allenex to launch new HLA typing technology in 2015

During 2014, Allenex has started the development of brand new HLA typing tests based on the method of real-time PCR. The aim is to launch the products during the second quarter of 2015. The advantage of the real-time PCR method is that it is simpler and faster compared to currently used HLA typing methods.

"We see great value in being able to offer Allenex customers worldwide HLA typing products based on the method of real-time PCR" says Allenex CEO Anders Karlsson, and he continues: "HLA typing based on the method of real-time PCR is more rapid and efficient. It is especially valuable for on-call deceased donor typing for solid organ transplantation. In these situations you need the testing done quickly and often outside of regular working hours, which place a high demand on simplicity and automation. We regard our upcoming new real-time PCR HLA typing product as a natural extension of our existing product line." he concludes.

Real-time PCR is already used today in many laboratories for other types of diagnosis, e.g. for cancer and infection diagnostics. It is, however, an underutilized analytical method for HLA typing, where Allenex currently is a world leader with the Olerup SSP products. The development project will run mainly internally at Allenex subsidiary Olerup SSP AB. These new products will be offered as an addition to the current products. As of today there is one competing product for this segment, but Allenex expects the usage to increase significantly in the years ahead. Allenex now sees an opportunity to attract new customers for our whole HLA typing product range. Today, Allenex presents this project at a conference in Denver, Colorado organized by ASHI (American Society for Histocompatibility and Immunogenetics)

SSP technology for transplantation matching, HLA typing, is the technology used today at most HLA typing laboratories in the world. Globally, more than 100,000 organ transplants are done annually and a low resolution HLA typing is a prerequisite, so that compatibility between donor and recipient can be guaranteed.

This first real-time PCR HLA typing product introduced by Allenex will target the low to intermediate resolution HLA typing needs for organ transplantation.

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on October 21, 2014, at 08.45 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.